OBJECTIVE—Posttransplantation diabetes mellitus (PTDM) is a major metabolic complication in renal transplant recipients, and insulin secretory defects play an important role in the pathogenesis of PTDM. The R325W (rs13266634) nonsynonymous polymorphism in the islet-specific zinc transporter protein gene, SLC30A8, has been reported to be associated with type 2 diabetes and possibly with a defect in insulin secretion. This study investigated the association between genetic variations in the SLC30A8 gene and PTDM in renal allograft recipients.

RESEARCH DESIGN AND METHODS—A total of 624 unrelated renal allograft recipients without previously diagnosed diabetes were enrolled. Rs13266634 was genotyped in the cohort, which consisted of 174 posttransplantation diabetic patients and 450 non-posttransplantation diabetic subjects. The genotyping of the SLC30A8 polymorphism was performed using real-time PCR.

RESULTS—The prevalence of PTDM was 33.8% in patients carrying the R/R genotype, 26.8% in patients with the R/W genotype, and 19.8% in patients with the W/W genotype. There was a strong association between the number of W-alleles and PTDM risk reduction (P for trend = 0.007). Patients with at least one T-allele showed a decreased risk of PTDM compared with those with the R/R genotype (R/W, risk ratio [RR] 0.78, P = 0.126; W/W, RR 0.52, P = 0.007). The effect of the SLC30A8 genotype remained significant after adjustments for age, sex, body weight gain, and type of immunosuppressant (R/W, hazard ratio [HR] 0.77, P = 0.114; W/W, HR 0.58, P = 0.026).

CONCLUSIONS—These data provide evidence that the SLC30A8 rs13266634 gene variation is associated with protection from the development of PTDM in renal allograft recipients.

Posttransplantation diabetes mellitus (PTDM) is a serious metabolic complication and is associated with cardiovascular morbidity and mortality (13). Patients with PTDM have an increased risk for long-term cardiovascular events of up to 3.27 times compared with those without PTDM (4). The incidence of PTDM ranges from 2 to 53% (5). A number of risk factors for PTDM have been reported, including older age, ethnicity, obesity, family history of diabetes, cadaver donor, frequent acute rejection, hepatitis C infection, corticosteroid dose, and type of immunosuppressant therapy (2,612). However, there are few studies on genetic risk factors for the development of PTDM (13,14).

Although many studies have reported that insulin resistance is important to the pathophysiology of PTDM, a defect in insulin secretion may also play a role in the development of PTDM (10,15). Insulin is stored in pancreatic β-cells as zinc-insulin crystals. Zinc is believed to be an important component of the insulin secretion mechanism and may modulate insulin secretion (1618). Zinc transporter (Znt)-8, expressed only in pancreatic β-cells, is thought to be the β-cell zinc regulator (1921). Recently, a polymorphism in the ZnT-8 gene (SLC30A8) has been associated with type 2 diabetes (2225). This single nucleotide polymorphism (SNP), rs13266634, is a nonsynonymous SNP causing an amino acid change from arginine (R) to tryptophan (W) at position 325. We investigated the association between the SLC30A8 polymorphism and the incidence of PTDM in renal allograft recipients.

A total of 805 unrelated transplant recipients were recruited from 1989 to 2007. PTDM was diagnosed according to American Diabetes Association criteria (26) at the 3rd month posttransplantation. Patients who were started on antidiabetic medication (oral medication or insulin) after transplantation and continued the medication thereafter were included in the posttransplantation diabetic group. The rest of the patients were assigned to the non- posttransplantation diabetic group. According to our previous study (15), cases of persistent PTDM (patients who developed diabetes within 1 year posttransplantation and remained diabetic) and late PTDM (patients who developed diabetes after 1 year posttransplantation) were assigned to the posttransplantation diabetic group. Transient PTDM cases (patients who developed diabetes within 1 year posttransplantation but eventually recovered to normoglycemia without medication) were classified as non-PTDM.

Patients were eligible to participate in the study if they were the recipients of a kidney allograft with no previous history of organ transplantation. Those with no previous diagnosis of diabetes and a recorded fasting plasma glucose (FPG) level <5.5 mmol/l were included. Patients were excluded if they had a history of diabetes before transplantation, severe metabolic or infectious disease, or a recorded FPG level ≥5.5 mmol/l. A total of 624 unrelated renal allograft recipients were enrolled in this study. Medical histories were obtained during the initial visit, and family history of diabetes refers to first-degree relatives only. Height and weight measurements were taken at the time of transplantation and at 3 and 6 months after transplantation. Blood samples were collected after an overnight fast. Frequency of patient follow-up and data collected at follow-up visits are shown in the online appendix (available at http://dx.doi.org/10.2337/db07-0761). Initial FPG level was measured on the day of transplantation using an enzymatic colorimetric assay. Insulin concentration was measured using a radioimmunoassay kit (Dainabot, Tokyo, Japan). Markers of insulin sensitivity and β-cell insulin secretory function were determined by the homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) and β-cell function (HOMA-β) (27). HOMA-IR was calculated as (fasting plasma insulin [μU/ml] × FPG [mmol/l])/22.5 and HOMA-β as (20 × fasting plasma insulin [μU/ml])/(FPG [mmol/l] − 3.5). The study protocol was approved by the ethics committee of the Yonsei University College of Medicine. All subjects were provided with adequate information about this study and gave informed consent.

Immunosuppression.

The immunosuppressive regimens consisted of calcineurin inhibitors and glucocorticoids. Immunosuppressive regimens and schedules were as reported previously (15) (online appendix).

DNA extraction and SLC30A8 genotyping.

Genomic DNA was isolated from peripheral blood lymphocytes. The genotyping of the SLC30A8 polymorphism rs13266634 was done using the TaqMan fluorogenic 5′ nuclease assay (ABI, Foster City, CA). The final reaction volume for the PCR was 5 μl, containing 10 ng genomic DNA, 2.5 μl TaqMan Universal PCR Master Mix, and 0.13 μl 40× Assay Mix (assay ID C2684958_10). Thermal cycling conditions were as follows: 50°C for 2 min to activate the uracil N-glycosylase and prevent carry-over contamination, 95°C for 10 min to activate the DNA polymerase, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. All PCRs were performed using 384-well plates by a Dual 384-Well GeneAmp PCR System 9700 (ABI), and the endpoint fluorescent readings were performed on an ABI PRISM 7900 HT Sequence Detection System. Forty-eight duplicate samples and negative controls were included to ensure the accuracy of genotyping, and 100% of the duplicates replicated the original genotype. The genotype success rate was 99.48% for rs13266634.

Statistical analyses.

The genotype frequencies were tested for Hardy-Weinberg equilibrium using χ2 test. All continuous variables were expressed as means ± SD. Student’s t test was used to compare continuous variables between the PTDM and non-PTDM posttransplantation diabetic groups. Pearson’s χ2 test was used to evaluate the difference in the incidence of diabetes between genotypes. ANOVA was used to compare continuous variables among genotypes. Mantel-Haenzel χ2 test (P for trend) was used to evaluate the trend of diabetes protection with an increase in number of W-alleles. Cox proportional hazards modeling was used to identify risk factors for PTDM development and calculate the adjusted hazard ratio [HR] and 95% CIs. Diabetes-free survival was calculated from the date of transplantation to the date of PTDM diagnosis or last follow-up. Survival was estimated by Kaplan-Meier method and compared using the log-rank test. Patient baseline characteristics were assessed on transplant day. A P value <0.05 was considered statistically significant. Statistical analyses were performed using SPSS for Windows software (version 12.0; SPSS, Chicago, IL). Power calculations were performed using PASS software version 2005 (NCSS Statistical Software, Kaysville, UT).

Clinical characteristics of posttransplantation diabetic patients.

The overall incidence of PTDM in this study population was 27.9%. Baseline clinical characteristics of the recipients are shown in Table 1. The mean age of patients at transplantation was 38.7 ± 9.5 years. Patients in the posttransplantation diabetic group were older than those in the non-posttransplantation diabetic group (42.10 ± 8.99 vs. 37.42 ± 9.43 years old, P = 0.001). Posttransplantation diabetic patients were followed up for a significantly longer period than non-posttransplantation diabetic patients. Baseline mean body weight was 58.83 ± 9.71 kg, and although initial body weight was not significantly different between the two groups, there was a significant difference in the amount of weight gain during the first 6 months after transplantation between the two groups (Table 1). The duration of dialysis, incidence of acute rejection, and serum creatinine levels were not different between the groups (Table 1). Patients who used tacrolimus as an immunosuppressive agent had a higher incidence of PTDM (P = 0.031). There was no significant difference in steroid dose between the groups (online appendix).

Genotype distribution.

The overall R-allele frequency was 0.577 and the overall W-allele frequency was 0.423. Overall genotype distributions were R/R, 33.17%; R/W, 49.04%; and W/W, 17.79%. Genotype distributions were in agreement with Hardy-Weinberg equilibrium (χ2 = 0.013, P = 0.910) (Table 2).

Association between the SLC30A8 rs13266634 genotype and PTDM.

PTDM developed in 174 patients (27.2%). The W/W genotype conferred a reduced risk for PTDM compared with the R/R genotype (risk ratio [RR] 0.52 [95% CI 0.32–0.83], P = 0.007; Table 2). The risk of PTDM was marginally lower in carriers of the R/W genotype than in R/R carriers (0.78 [0.57–1.07], P = 0.126, Table 2). The W-allele was associated with a decreased incidence of PTDM in codominant (R/R, 33.8%; R/W 26.8%; W/W, 19.8%; P = 0.025), dominant (R/R, 33.8%; R/W plus W/W, 24.9%; P = 0.024), and recessive (R/R plus R/W, 29.6%; W/W, 19.8%; P = 0.038) models (Table 2).

There was no difference among genotypes in age at transplantation, initial body weight, amount of body weight gain, FPG level (at baseline and at 3, 6, and 12 months after transplantation), duration of dialysis, percentage of tacrolimus use as an immunosuppressant, incidence of acute rejection, or serum creatinine levels (Table 3).

There was a linear increase in the HOMA-β value from the R/R genotype to the W/W genotype. Insulin secretory function, assessed by HOMA-β, was better preserved in patients with the W/W genotype than in those with the R/R genotype (Table 3). In contrast, no significant difference in HOMA-IR value according to genotype was observed (Table 3).

Independent risk factors of PTDM were identified using multiple Cox proportional hazard regression. We included age, sex, amount of body weight gain, type of immunosuppressant, and genotype as covariates in the multiple Cox proportional hazard regression model because they were associated with PTDM in univariate association tests (Table 1). As shown in Table 4, the SLC30A8 genotype was a significant independent risk factor of PTDM together with age at transplantation and tacrolimus use as an immunosuppressant. The effect of the genotype remained significant after adjustments for age, sex, amount of weight gain, and type of immunosuppressant used (R/W, HR 0.77, P = 0.114; W/W, HR 0.58, P = 0.026). Age, amount of weight gain, and tacrolimus use were associated with PTDM development, but sex was not (Table 4).

The Kaplan-Meier curve for the development of PTDM is shown in Fig. 1. Patients with the W/W genotype had a significantly lower risk (P = 0.007) of developing PTDM than those with the R/R genotype.

Zinc is thought to be an important metal for insulin storage and secretion (16). Zinc homeostasis is regulated by the uptake and export of zinc by specialized transporter proteins. Insulin is stored inside secretory granules as solid hexamers bound with two Zn2+ ions per hexamer (17,18). Zinc is likely to play a role in the stability of the insulin hexamer and to modulate glucagon secretion in α-cells via paracrine action.

The SLC39 proteins (Zips) control the intracellular uptake of zinc (28), and SLC30 proteins (ZnTs) control the cellular efflux of zinc into the extracellular matrix or intracellular vesicles (29). Among ZnTs, ZnT-8 has recently been identified and cloned as a pancreatic β-cell–specific ZnT and is located in insulin secretory granules (1921). ZnT-8 is encoded by the gene SLC30A8, which is located at chromosome 8q24.11. The polymorphism rs1326634 in the SLC30A8 gene has been associated with type 2 diabetes (2225). In addition, recent studies have suggested that SLC30A8 may play a role in insulin secretion in the process of zinc incorporation into insulin vesicles (19,20).

In this study, we demonstrated the genetic influence of the SLC30A8 polymorphism in the development of PTDM in a renal transplant cohort. We calculated the relative risks of the heterozygote R/W genotype and the mutant homozygote W/W genotype compared with the wild homozygote R/R genotype because the risk allele was the major allele (R) in a previously reported French study (22). We found the risk of PTDM to be significantly lower in patients who were W/W homozygotes than in patients who were R/R wild-type homozygotes. There was also a tendency toward a reduction in the risk of PTDM in R/W heterozygote carriers compared with R/R carriers. We observed a linear relationship between the number of R-alleles and an increased incidence of PTDM. This genotype effect remained significant after adjustments for age, sex, amount of body weight gain, and type of immunosuppressant use. These results suggest that the SLC30A8 gene is one susceptibility gene for PTDM. Age at transplantation and tacrolimus use as an immunosuppressant were revealed as important risk factors for PTDM.

Interestingly, there was a higher mean HOMA-β value in patients carrying the W/W genotype than in those carrying the R/R genotype. These results suggest that this polymorphism may be functional and have effects on insulin secretion. There was no significant difference in HOMA-IR value according to genotype. Numakura et al. (13) reported that a vitamin D receptor (VDR) polymorphism was associated with PTDM in 70 renal allograft recipients. The VDR polymorphism is also reported to affect insulin secretion (3032). Their results and the results of this study are consistent with our previous reports (10,15), in that a defect in insulin secretion plays a more crucial role than increased insulin resistance in the pathogenesis of PTDM.

This SLC30A8 polymorphism site is located at the COOH-terminal region of the protein structure. The rs1326634 SNP results in a nonsynonymous mutation because the nucleotide change from C to T results in an amino acid change from arginine (R) to tryptophan (W) at position 325. This polymorphism might be a gain-of- function mutation that increases protein expression levels, thereby enhancing zinc transport into insulin secretory granules. Facilitated zinc transport could influence insulin stability and secretion. Another possibility is that the polymorphism may affect the posttranslational modification mechanism in the COOH terminus of ZnT-8. Until now, information on ZnT-interacting proteins or phosphorylation events in the intracellular COOH termini of all the ZnT subfamily members has been lacking. Interestingly, the amino acid stretch (TAASR*DSQVV) constituting R325 in the COOH terminus of ZnT-8 has a protein kinase A and protein kinase C recognition motif (R-X-S/T). The R325W polymorphism would disrupt this motif, which may possibly prevent the receptor phosphorylation otherwise regulated by serine protein kinases, leading to changes in the transporter function. There is much that still needs to be learned about the regulation of ZnT, and the exact molecular mechanisms remain to be elucidated.

A limitation of this study is that oral glucose tolerance tests were not routinely performed before transplantation. Preexisting diabetes could lead to an overestimation in the diagnosis of PTDM. There may also be a bias toward the null because non-posttransplantation diabetic patients were followed up for a shorter duration and may have been misclassified. Another limitation is the relatively small sample size. Thus, our study had 51% power to detect an inverted reference odds ratio of 0.65 (1/1.53) at α = 0.05 (22). Further analyses are warranted to replicate the associations in larger populations.

In conclusion, our data suggest that the SLC30A8 rs1326634 variant is associated with a decreased risk of PTDM and may be associated with insulin secretion. The exact molecular mechanisms still need to be clarified.

FIG. 1.

Cumulative diabetes-free survival (by the Kaplan Meier method) in the development of PTDM for patients with the R/R, R/W, and W/W genotypes.

FIG. 1.

Cumulative diabetes-free survival (by the Kaplan Meier method) in the development of PTDM for patients with the R/R, R/W, and W/W genotypes.

TABLE 1

Clinical characteristics of the study population

PTDMNon-PTDMP
n (% women) 174 (35.1) 450 (35.6) 0.907* 
Age at transplantation (years) 42.10 ± 8.99 35.42 ± 9.43 0.001 
Family history of diabetes (%) 100 (57.5) 256 (56.9) 0.895* 
Follow-up duration (months) 113.02 ± 58.53 100.36 ± 62.26 0.018 
BW at transplantation (kg) 59.01 ± 9.69 58.76 ± 9.72 0.771 
BW at 3 months after transplantation (kg) 59.58 ± 9.32 58.54 ± 8.74 0.205 
BW at 6 months after transplantation (kg) 62.68 ± 8.83 60.87 ± 8.99 0.023 
ΔBW during first 3 months after transplantation (kg) −0.57 ± 4.83 −0.21 ± 4.29 0.061 
ΔBW during first 6 months after transplantation (kg) 3.66 ± 5.76 2.12 ± 5.22 0.002 
FPG at transplantation (mmol/l) 5.31 ± 1.35 5.16 ± 1.44 0.254 
FPG at 3 months after transplantation (mmol/l) 6.90 ± 3.61 5.34 ± 0.78 <0.001 
FPG at 6 months after transplantation (mmol/l) 6.81 ± 3.18 5.32 ± 0.73 <0.001 
FPG at 12 months after transplantation (mmol/l) 6.93 ± 2.85 5.41 ± 0.85 <0.001 
Duration of dialysis (months) 17.48 ± 23.96 19.47 ± 29.98 0.449 
No. of patients with acute rejection (%) 51 (29.3) 111 (24.7) 0.235* 
No. of patients with tacrolimus use (%) 47 (27.0) 86 (19.1) 0.031* 
Cr at 3 months after transplantation (mg/dl) 1.34 ± 0.43 1.36 ± 0.39 0.590 
Cr at 6 months after transplantation (mg/dl) 1.31 ± 0.42 1.32 ± 0.34 0.749 
Cr at 12 months after transplantation (mg/dl) 1.28 ± 0.42 1.33 ± 0.45 0.204 
PTDMNon-PTDMP
n (% women) 174 (35.1) 450 (35.6) 0.907* 
Age at transplantation (years) 42.10 ± 8.99 35.42 ± 9.43 0.001 
Family history of diabetes (%) 100 (57.5) 256 (56.9) 0.895* 
Follow-up duration (months) 113.02 ± 58.53 100.36 ± 62.26 0.018 
BW at transplantation (kg) 59.01 ± 9.69 58.76 ± 9.72 0.771 
BW at 3 months after transplantation (kg) 59.58 ± 9.32 58.54 ± 8.74 0.205 
BW at 6 months after transplantation (kg) 62.68 ± 8.83 60.87 ± 8.99 0.023 
ΔBW during first 3 months after transplantation (kg) −0.57 ± 4.83 −0.21 ± 4.29 0.061 
ΔBW during first 6 months after transplantation (kg) 3.66 ± 5.76 2.12 ± 5.22 0.002 
FPG at transplantation (mmol/l) 5.31 ± 1.35 5.16 ± 1.44 0.254 
FPG at 3 months after transplantation (mmol/l) 6.90 ± 3.61 5.34 ± 0.78 <0.001 
FPG at 6 months after transplantation (mmol/l) 6.81 ± 3.18 5.32 ± 0.73 <0.001 
FPG at 12 months after transplantation (mmol/l) 6.93 ± 2.85 5.41 ± 0.85 <0.001 
Duration of dialysis (months) 17.48 ± 23.96 19.47 ± 29.98 0.449 
No. of patients with acute rejection (%) 51 (29.3) 111 (24.7) 0.235* 
No. of patients with tacrolimus use (%) 47 (27.0) 86 (19.1) 0.031* 
Cr at 3 months after transplantation (mg/dl) 1.34 ± 0.43 1.36 ± 0.39 0.590 
Cr at 6 months after transplantation (mg/dl) 1.31 ± 0.42 1.32 ± 0.34 0.749 
Cr at 12 months after transplantation (mg/dl) 1.28 ± 0.42 1.33 ± 0.45 0.204 

Data are means ± SD or n (%) unless otherwise indicated. BW, body weight; ΔBW, change in body weight. P values were calculated from t test.

*

P values were calculated from the χ2 test.

Included patients with antidiabetic medications.

TABLE 2

Genotype distribution and corresponding RR for PTDM

GenotypePTDMNon-PTDMGenotype effect
Codominant model
Recessive model
Dominant model
RR (95% CI)PRR (95% CI)PRR (95% CI)P
R/R 70 (40.2)* 137 (30.4)      
R/W 82 (47.1)* 224 (49.8) 0.78 (0.57–1.07) 0.126     
W/W 22 (12.6)* 89 (19.8) 0.52 (0.32–0.84) 0.007 0.60 (0.38–0.94) 0.038 0.70 (0.52–0.96) 0.024 
GenotypePTDMNon-PTDMGenotype effect
Codominant model
Recessive model
Dominant model
RR (95% CI)PRR (95% CI)PRR (95% CI)P
R/R 70 (40.2)* 137 (30.4)      
R/W 82 (47.1)* 224 (49.8) 0.78 (0.57–1.07) 0.126     
W/W 22 (12.6)* 89 (19.8) 0.52 (0.32–0.84) 0.007 0.60 (0.38–0.94) 0.038 0.70 (0.52–0.96) 0.024 

Data are n (%) unless otherwise indicated. The codominant model represents comparisons between R/R versus R/W genotypes and R/R versus W/W genotypes. The recessive model represents the comparison between the R/R plus R/W versus W/W genotypes. The dominant model represents the comparison of the R/R versus R/W plus W/W genotypes.

*

P = 0.025 when comparing three groups using χ2 test and P = 0.007 when calculated from the Mantel-Haenzel χ2 test (P trend test).

TABLE 3

Characteristics of patients according to rs13266634 genotype

R/RR/WW/WP
n (% female) 207 (35.7) 306 (37.9) 111 (27.9) 0.168* 
No. of PTDM patients (%) 70 (33.8) 82 (26.8) 22 (19.8) 0.025* 0.007 
Age at transplantation (years) 39.60 ± 9.71 38.34 ± 9.06 38.16 ± 10.41 0.269 
Family history of diabetes (%) 119 (57.5) 172 (56.2) 65 (58.6) 0.901* 
Follow-up duration (months) 103.66 ± 62.15 101.86 ± 59.71 109.94 ± 65.03 0.495 
BW at transplantation (kg) 59.09 ± 9.22 58.70 ± 10.40 58.27 ± 8.31 0.891 
BW at 3 months after transplantation (kg) 59.01 ± 8.71 58.91 ± 9.28 58.27 ± 8.31 0.762 
BW at 6 months after transplantation (kg) 61.28 ± 8.91 61.59 ± 9.27 60.98 ± 8.34 0.819 
ΔBW during first 3 months after transplantation (kg) −0.09 ± 4.61 0.22 ± 4.30 −0.40 ± 4.63 0.430 
ΔBW during first 6 months after transplantation (kg) 2.20 ± 5.32 2.88 ± 5.43 2.31 ± 5.55 0.338 
FPG at transplantation (mmol/l) 5.32 ± 1.66 5.18 ± 1.35 5.05 ± 1.06 0.316 
FPG at 3 months after transplantation (mmol/l) 5.97 ± 2.02 5.73 ± 2.46 5.53 ± 1.00 0.334 
FPG at 6 months after transplantation (mmol/l) 5.74 ± 1.85 5.78 ± 2.12 5.49 ± 0.87 0.527 
FPG at 12 months after transplantation (mmol/l) 6.00 ± 2.16 5.85 ± 1.80 5.47 ± 0.73 0.060 
HOMA-IR at 12 months after transplantation 3.21 ± 1.45 3.02 ± 1.62 3.94 ± 1.99 0.304 
HOMA-β at 12 months after transplantation 66.12 ± 45.35 112.41 ± 60.18§ 188.32 ± 124.85 0.001 
Duration of dialysis (months) 22.13 ± 31.64 16.40 ± 25.78 20.16 ± 35.90 0.079 
No. of patients with acute rejection (%) 57 (27.5) 77 (25.2) 28 (25.2) 0.819* 
No. of patients with tacrolimus use (%) 49 (23.7) 64 (20.9) 20 (18.0) 0.488* 
Cr at 3 months after transplantation (mg/dl) 1.36 ± 0.43 1.33 ± 0.38 1.42 ± 0.38 0.099 
Cr at 6 months after transplantation (mg/dl) 1.31 ± 0.38 1.31 ± 0.37 1.36 ± 0.30 0.517 
Cr at 12 months after transplantation (mg/dl) 1.31 ± 0.50 1.30 ± 0.38 1.36 ± 0.49 0.481 
R/RR/WW/WP
n (% female) 207 (35.7) 306 (37.9) 111 (27.9) 0.168* 
No. of PTDM patients (%) 70 (33.8) 82 (26.8) 22 (19.8) 0.025* 0.007 
Age at transplantation (years) 39.60 ± 9.71 38.34 ± 9.06 38.16 ± 10.41 0.269 
Family history of diabetes (%) 119 (57.5) 172 (56.2) 65 (58.6) 0.901* 
Follow-up duration (months) 103.66 ± 62.15 101.86 ± 59.71 109.94 ± 65.03 0.495 
BW at transplantation (kg) 59.09 ± 9.22 58.70 ± 10.40 58.27 ± 8.31 0.891 
BW at 3 months after transplantation (kg) 59.01 ± 8.71 58.91 ± 9.28 58.27 ± 8.31 0.762 
BW at 6 months after transplantation (kg) 61.28 ± 8.91 61.59 ± 9.27 60.98 ± 8.34 0.819 
ΔBW during first 3 months after transplantation (kg) −0.09 ± 4.61 0.22 ± 4.30 −0.40 ± 4.63 0.430 
ΔBW during first 6 months after transplantation (kg) 2.20 ± 5.32 2.88 ± 5.43 2.31 ± 5.55 0.338 
FPG at transplantation (mmol/l) 5.32 ± 1.66 5.18 ± 1.35 5.05 ± 1.06 0.316 
FPG at 3 months after transplantation (mmol/l) 5.97 ± 2.02 5.73 ± 2.46 5.53 ± 1.00 0.334 
FPG at 6 months after transplantation (mmol/l) 5.74 ± 1.85 5.78 ± 2.12 5.49 ± 0.87 0.527 
FPG at 12 months after transplantation (mmol/l) 6.00 ± 2.16 5.85 ± 1.80 5.47 ± 0.73 0.060 
HOMA-IR at 12 months after transplantation 3.21 ± 1.45 3.02 ± 1.62 3.94 ± 1.99 0.304 
HOMA-β at 12 months after transplantation 66.12 ± 45.35 112.41 ± 60.18§ 188.32 ± 124.85 0.001 
Duration of dialysis (months) 22.13 ± 31.64 16.40 ± 25.78 20.16 ± 35.90 0.079 
No. of patients with acute rejection (%) 57 (27.5) 77 (25.2) 28 (25.2) 0.819* 
No. of patients with tacrolimus use (%) 49 (23.7) 64 (20.9) 20 (18.0) 0.488* 
Cr at 3 months after transplantation (mg/dl) 1.36 ± 0.43 1.33 ± 0.38 1.42 ± 0.38 0.099 
Cr at 6 months after transplantation (mg/dl) 1.31 ± 0.38 1.31 ± 0.37 1.36 ± 0.30 0.517 
Cr at 12 months after transplantation (mg/dl) 1.31 ± 0.50 1.30 ± 0.38 1.36 ± 0.49 0.481 

Data are means ± SD or n (%). BW, body weight; ΔBW, change in body weight. P values were calculated from t test.

*

P values were calculated from χ2 test.

P value was calculated from the Mantel-Haenzel χ2 test (trend P test).

P = 0.001 (post-hoc analysis between R/R and W/W genotypes).

§

P = 0.016 (post-hoc analysis between R/W and W/W genotypes).

TABLE 4

Multivariable Cox proportional hazard regression analysis of risk factors associated with PTDM

HR (95% CI)P
Age (years) 1.05 (1.03–1.07) <0.001 
Sex (0 = men, 1 = women) 0.93 (0.67–1.27) 0.780 
ΔBW at 6 months after transplantation 1.03 (1.00–1.06) 0.036 
Immunosuppressant (0 = cyclosporine A, 1 = tacrolimus) 2.66 (1.85–3.82) <0.001 
Genotype (0 = R/R, 1 = R/W) 0.77 (0.56–1.06) 0.114 
Genotype (0 = R/R, 1 = W/W) 0.58 (0.36–0.94) 0.026 
HR (95% CI)P
Age (years) 1.05 (1.03–1.07) <0.001 
Sex (0 = men, 1 = women) 0.93 (0.67–1.27) 0.780 
ΔBW at 6 months after transplantation 1.03 (1.00–1.06) 0.036 
Immunosuppressant (0 = cyclosporine A, 1 = tacrolimus) 2.66 (1.85–3.82) <0.001 
Genotype (0 = R/R, 1 = R/W) 0.77 (0.56–1.06) 0.114 
Genotype (0 = R/R, 1 = W/W) 0.58 (0.36–0.94) 0.026 

ΔBW, change in body weight between baseline and 3 months after transplantation.

Published ahead of print at http://diabetes.diabetesjournals.org on 25 January 2008. DOI: 10.2337/db07-0761.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0761.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work has received a Korea Research Foundation grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2007-331-E00081).

1.
Ducloux D, Kazory A, Chalopin JM: Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study.
Transplantation
79
:
438
–443,
2005
2.
Rodrigo E, Fernandez-Fresnedo G, Valero R, Ruiz JC, Pinera C, Palomar R, Gonzalez-Cotorruelo J, Gomez-Alamillo C, Arias M: New-onset diabetes after kidney transplantation: risk factors.
J Am Soc Nephrol
17
:
S291
–S295,
2006
3.
Fernandez-Fresnedo G, Escallada R, de Francisco AL, Rodrigo E, Zubimendi JA, Ruiz JC, Pinera C, Herraez I, Arias M: Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients.
Transplant Proc
35
:
700
,
2003
4.
Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T: The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events.
Kidney Int
69
:
588
–595,
2006
5.
Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: a systematic review of the literature.
Diabetes Care
25
:
583
–592,
2002
6.
Hathaway DK, Tolley EA, Blakely ML, Winsett RP, Gaber AO: Development of an index to predict posttransplant diabetes mellitus.
Clin Transplant
7
:
330
–338,
1993
7.
Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function.
Kidney Int
57
:
307
–313,
2000
8.
Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States.
Am J Transplant
3
:
178
–185,
2003
9.
Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.
Am J Transplant
4
:
583
–595,
2004
10.
Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus.
Transplantation
71
:
1417
–1423,
2001
11.
Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P: Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors.
Transplantation
61
:
1475
–1478,
1996
12.
Sumrani N, Delaney V, Ding Z, Davis R, Daskalakis P, Friedman EA, Butt KM, Hong JH: Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients.
Transplant Proc
23
:
1249
–1250,
1991
13.
Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, Saito M, Tada H, Suzuki T, Habuchi T: Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus.
Transplantation
80
:
1419
–1424,
2005
14.
Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D: IL-6 promoter polymorphism −174 is associated with new-onset diabetes after transplantation.
J Am Soc Nephrol
17
:
2333
–2340,
2006
15.
Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC: Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients.
Diabetes Care
30
:
609
–615,
2007
16.
Chausmer AB: Zinc, insulin and diabetes.
J Am Coll Nutr
17
:
109
–115,
1998
17.
Emdin SO, Dodson GG, Cutfield JM, Cutfield SM: Role of zinc in insulin biosynthesis: some possible zinc-insulin interactions in the pancreatic B-cell.
Diabetologia
19
:
174
–182,
1980
18.
Dodson G, Steiner D: The role of assembly in insulin’s biosynthesis.
Curr Opin Struct Biol
8
:
189
–194,
1998
19.
Chimienti F, Devergnas S, Favier A, Seve M: Identification and cloning of a β-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules.
Diabetes
53
:
2330
–2337,
2004
20.
Chimienti F, Devergnas S, Pattou F, Schuit F, Garcia-Cuenca R, Vandewalle B, Kerr-Conte J, Van Lommel L, Grunwald D, Favier A, Seve M: In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion.
J Cell Sci
119
:
4199
–4206,
2006
21.
Chimienti F, Favier A, Seve M: ZnT-8, a pancreatic beta-cell-specific zinc transporter.
Biometals
18
:
313
–317,
2005
22.
Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes.
Nature
445
:
881
–885,
2007
23.
Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.
Science
316
:
1341
–1345,
2007
24.
Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorradottir S, Bjarnason H, Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RC, Andersen G, Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K: A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.
Nat Genet
39
:
770
–775,
2007
25.
Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UKsamples reveals risk loci for type 2 diabetes.
Science
316
:
1336
–1341,
2007
26.
Diagnosis and classification of diabetes mellitus.
Diabetes Care
30
(Suppl. 1):
S42
–S47,
2007
27.
Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R: Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test.
Diabetologia
43
:
1507
–1511,
2000
28.
Eide DJ: The SLC39 family of metal ion transporters.
Pflugers Arch
447
:
796
–800,
2004
29.
Seve M, Chimienti F, Devergnas S, Favier A: In silico identification and expression of SLC30 family genes: an expressed sequence tag data mining strategy for the characterization of zinc transporters’ tissue expression.
BMC Genomics
5
:
32
,
2004
30.
Hitman GA, Mannan N, McDermott MF, Aganna E, Ogunkolade BW, Hales CN, Boucher BJ: Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians.
Diabetes
47
:
688
–690,
1998
31.
Bourlon PM, Faure-Dussert A, Billaudel B, Sutter BC, Tramu G, Thomasset M: Relationship between calbindin-D28K levels in the A and B cells of the rat endocrine pancreas and the secretion of insulin and glucagon: influence of vitamin D3 deficiency and 1,25-dihydroxyvitamin D3.
J Endocrinol
148
:
223
–232,
1996
32.
Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K, North BV, Mannan N, McDermott MF, DeLuca HF, Hitman GA: Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians.
Diabetes
51
:
2294
–2300,
2002

Supplementary data